vs
LiveOne, Inc.（LVO）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是LiveOne, Inc.的1.5倍（$30.3M vs $20.3M），LiveOne, Inc.净利率更高（-20.1% vs -221.3%，领先201.3%），REGENXBIO Inc.同比增速更快（43.0% vs -31.2%），LiveOne, Inc.自由现金流更多（$-2.9M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -19.0%）
Live Nation Entertainment是一家美国跨国娱乐企业，2010年由原Live Nation与Ticketmaster合并成立。目前两大品牌仍作为子品牌独立运营，业务覆盖全球现场娱乐演出推广与票务销售，同时自营多座娱乐场馆，也提供艺人经纪管理服务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
LVO vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.5倍
$20.3M
营收增速更快
RGNX
高出74.2%
-31.2%
净利率更高
LVO
高出201.3%
-221.3%
自由现金流更多
LVO
多$49.9M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-19.0%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $20.3M | $30.3M |
| 净利润 | $-4.1M | $-67.1M |
| 毛利率 | 18.8% | — |
| 营业利润率 | -9.6% | -190.0% |
| 净利率 | -20.1% | -221.3% |
| 营收同比 | -31.2% | 43.0% |
| 净利润同比 | 22.3% | -31.2% |
| 每股收益（稀释后） | — | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LVORGNX
| Q4 25 | $20.3M | $30.3M | ||
| Q3 25 | $18.8M | $29.7M | ||
| Q2 25 | $19.2M | $21.4M | ||
| Q1 25 | $19.3M | $89.0M | ||
| Q4 24 | $29.4M | $21.2M | ||
| Q3 24 | $32.6M | $24.2M | ||
| Q2 24 | $33.1M | $22.3M | ||
| Q1 24 | $30.9M | $15.6M |
净利润LVORGNX
| Q4 25 | $-4.1M | $-67.1M | ||
| Q3 25 | $-5.5M | $-61.9M | ||
| Q2 25 | $-3.6M | $-70.9M | ||
| Q1 25 | $-10.4M | $6.1M | ||
| Q4 24 | $-5.2M | $-51.2M | ||
| Q3 24 | $-1.9M | $-59.6M | ||
| Q2 24 | $-1.2M | $-53.0M | ||
| Q1 24 | $-2.3M | $-63.3M |
毛利率LVORGNX
| Q4 25 | 18.8% | — | ||
| Q3 25 | 13.8% | — | ||
| Q2 25 | 12.4% | — | ||
| Q1 25 | 30.8% | — | ||
| Q4 24 | 24.3% | 70.2% | ||
| Q3 24 | 24.8% | 48.8% | ||
| Q2 24 | 24.2% | 52.5% | ||
| Q1 24 | 25.5% | 72.6% |
营业利润率LVORGNX
| Q4 25 | -9.6% | -190.0% | ||
| Q3 25 | -24.4% | -176.3% | ||
| Q2 25 | -21.0% | -296.3% | ||
| Q1 25 | -55.8% | 13.6% | ||
| Q4 24 | -17.4% | -242.1% | ||
| Q3 24 | -4.3% | -256.6% | ||
| Q2 24 | -2.4% | -251.3% | ||
| Q1 24 | -3.7% | -408.8% |
净利率LVORGNX
| Q4 25 | -20.1% | -221.3% | ||
| Q3 25 | -29.5% | -208.3% | ||
| Q2 25 | -18.7% | -331.8% | ||
| Q1 25 | -54.2% | 6.8% | ||
| Q4 24 | -17.8% | -241.3% | ||
| Q3 24 | -5.7% | -246.3% | ||
| Q2 24 | -3.5% | -237.7% | ||
| Q1 24 | -7.4% | -405.4% |
每股收益（稀释后）LVORGNX
| Q4 25 | — | $-1.30 | ||
| Q3 25 | — | $-1.20 | ||
| Q2 25 | — | $-1.38 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | — | $-1.17 | ||
| Q2 24 | — | $-1.05 | ||
| Q1 24 | — | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.6M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-19.0M | $102.7M |
| 总资产 | $52.3M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LVORGNX
| Q4 25 | $8.6M | $230.1M | ||
| Q3 25 | $11.7M | $274.2M | ||
| Q2 25 | $11.9M | $323.3M | ||
| Q1 25 | $4.1M | $267.9M | ||
| Q4 24 | $10.9M | $234.7M | ||
| Q3 24 | $11.1M | $255.5M | ||
| Q2 24 | $6.2M | $290.4M | ||
| Q1 24 | $7.0M | $338.7M |
股东权益LVORGNX
| Q4 25 | $-19.0M | $102.7M | ||
| Q3 25 | $-16.2M | $161.5M | ||
| Q2 25 | $-20.8M | $213.7M | ||
| Q1 25 | $-17.8M | $274.2M | ||
| Q4 24 | $-8.4M | $259.7M | ||
| Q3 24 | $-4.7M | $301.4M | ||
| Q2 24 | $-3.8M | $348.3M | ||
| Q1 24 | $-8.7M | $390.7M |
总资产LVORGNX
| Q4 25 | $52.3M | $453.0M | ||
| Q3 25 | $53.8M | $525.2M | ||
| Q2 25 | $48.9M | $581.0M | ||
| Q1 25 | $40.5M | $490.9M | ||
| Q4 24 | $56.2M | $466.0M | ||
| Q3 24 | $67.2M | $519.1M | ||
| Q2 24 | $64.6M | $569.4M | ||
| Q1 24 | $63.9M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.3M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-2.9M | $-52.8M |
| 自由现金流率自由现金流/营收 | -14.4% | -174.0% |
| 资本支出强度资本支出/营收 | 3.2% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-16.2M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流LVORGNX
| Q4 25 | $-2.3M | $-52.3M | ||
| Q3 25 | $-3.2M | $-56.0M | ||
| Q2 25 | $-3.0M | $-49.3M | ||
| Q1 25 | $-4.3M | $33.6M | ||
| Q4 24 | $3.5M | $-31.6M | ||
| Q3 24 | $5.8M | $-40.5M | ||
| Q2 24 | $1.3M | $-45.5M | ||
| Q1 24 | $3.0M | $-55.5M |
自由现金流LVORGNX
| Q4 25 | $-2.9M | $-52.8M | ||
| Q3 25 | $-4.0M | $-56.5M | ||
| Q2 25 | $-4.1M | $-49.7M | ||
| Q1 25 | $-5.2M | $32.6M | ||
| Q4 24 | $2.7M | $-32.7M | ||
| Q3 24 | $5.2M | $-40.9M | ||
| Q2 24 | $606.0K | $-46.0M | ||
| Q1 24 | $2.1M | $-56.0M |
自由现金流率LVORGNX
| Q4 25 | -14.4% | -174.0% | ||
| Q3 25 | -21.5% | -189.9% | ||
| Q2 25 | -21.2% | -232.8% | ||
| Q1 25 | -26.9% | 36.6% | ||
| Q4 24 | 9.2% | -154.2% | ||
| Q3 24 | 15.9% | -168.9% | ||
| Q2 24 | 1.8% | -206.2% | ||
| Q1 24 | 6.8% | -358.5% |
资本支出强度LVORGNX
| Q4 25 | 3.2% | 1.7% | ||
| Q3 25 | 4.4% | 1.7% | ||
| Q2 25 | 5.3% | 1.8% | ||
| Q1 25 | 4.8% | 1.2% | ||
| Q4 24 | 2.7% | 5.1% | ||
| Q3 24 | 1.8% | 1.3% | ||
| Q2 24 | 2.2% | 2.1% | ||
| Q1 24 | 3.1% | 3.6% |
现金转化率LVORGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LVO
| Advertising | $15.8M | 78% |
| Membership Services | $2.9M | 14% |
| Merchandising Revenue | $1.6M | 8% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
